Health Care·Pharmaceuticals·$2.2B
Phibro Animal Health Class A (PAHC) is a healthcare company focused on developing and manufacturing products for the animal health market. With a market cap of $2 billion, it plays a crucial role in the pharmaceuticals sector, particularly in providing solutions that enhance animal health and productivity.
EPS
Earnings per share is a key indicator of profitability and helps investors gauge the company's financial health.
Revenue
Revenue figures provide insight into the company's sales performance and market demand for its products.
Wall Street expectations, options signals, track record, and call prep available with Pro.
EPS Beat Streak
8Q
EPS Beat Rate
100%
Avg EPS Surprise
+24.02%
Avg Stock Reaction
+0.17%
In Q2-2026, Phibro reported an EPS of $0.87, significantly exceeding the estimate of $0.69, marking a 27% surprise. However, the stock price fell by 0.75% the following day, indicating potential market skepticism despite the strong earnings.
Management Promises & Guidance
Analysts expect Phibro to continue its trend of outperforming estimates, with a consensus EPS of $0.71 and revenue of $367 million. The company has consistently beaten EPS estimates in recent quarters, which could set a positive tone for this report.
Bull Case
If Phibro can deliver strong earnings and revenue growth, it may reinforce investor confidence and lead to a stock price increase, especially given its history of beating estimates.
Bear Case
Conversely, if the company fails to meet expectations or provides weak guidance, it could lead to a decline in stock price, particularly given the recent drop in share value following previous earnings.
EPS
$0.71Earnings per share is a key indicator of profitability and helps investors gauge the company's financial health.
Revenue
$367MRevenue figures provide insight into the company's sales performance and market demand for its products.
The print will turn on these two things.
Q1
Will the EPS exceed the consensus estimate of $0.71?
Given Phibro's strong history of beating EPS estimates, this will be a critical factor in determining market sentiment.
Q2
What will management say about revenue growth relative to the $367 million consensus?
Revenue growth is essential for assessing the company's market position and future prospects, especially in a competitive industry.
Why consensus could be wrong
The Street may underestimate the potential for Phibro to exceed expectations due to its strong product pipeline and market demand.
Supporting Evidence
Phibro has consistently beaten EPS estimates, indicating a trend of strong performance.
The options market is pricing in a significant move, suggesting that traders expect volatility and potential upside.
Recent earnings surprises have not translated into positive stock movements, indicating a disconnect between performance and market perception.
Key Risk
If revenue growth significantly exceeds $367 million, it could challenge the current consensus and lead to a reevaluation of the stock's potential.
Pre-commit to what would confirm each case.
This quarter's performance is crucial as it will either reinforce Phibro's growth trajectory or raise concerns about its ability to sustain momentum.
Bull Confirmed If
An EPS of $0.75 or higher would confirm the bull case, indicating strong operational performance.
Bear Confirmed If
An EPS below $0.70 would support the bear case, suggesting potential issues in meeting market expectations.
Implied Move
±10.43%
Historical Avg
±1.6%
The options market is pricing in a significant move of over 10%, suggesting that traders anticipate volatility around the earnings announcement.
Options are pricing ±10.4% while PAHC has averaged ±1.6% over the last 8 prints — setup is pricing rich.
Likely market behavior by outcome — not investment advice.
Beat & Raise
If Phibro beats estimates, history suggests a potential stock increase of around 0.17%, confirming the company's strong performance.
In-Line / Cautious
If results are in line with expectations, the stock may experience a muted reaction, reflecting cautious investor sentiment.
Miss
A miss could lead to a decline in stock price, with historical patterns suggesting an average drop of around 1.56%.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
PARAMOUNT SKYDANCE C Class B
May 4, 2026